Analysts Are Bullish on These Healthcare Stocks: MEI Pharma (MEIP), uniQure NV (QURE)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (NASDAQ:MEIP) and uniQure NV (NASDAQ:QURE) with bullish sentiments.

MEI Pharma (MEIP)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on MEI Pharma today and set a price target of $7.50. The company’s shares opened today at $3.56.

Cann commented:

“We currently anticipate ME-401 being filed with FDA in 2021 and that the drug could launch in 2022 with sales of $620.6 million by 2023. The collaboration with BeiGene, to study ME-401 in combination with zanubrutnib, could result in data that expands ME-401’s potential use beyond our current outlook. The results of the phase Ib study, presented at 2018 ASCO, were very impressive, with ORR of 90%. In addition to these data, we believe the combination studies with rituximab and with zanubrutinib could expand the number of addressable patients for ME-401. ME-401 is one of four development stage assets in MEI Pharma’s portfolio and is the second most advanced.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 12.0% and a 46.0% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.

MEI Pharma has an analyst consensus of Strong Buy, with a price target consensus of $8.83.

See today’s analyst top recommended stocks >>

uniQure NV (QURE)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on uniQure NV today and set a price target of $48. The company’s shares opened today at $26.50.

Chattopadhyay observed:

“Our $48 price target, is based on a 13-year DCF analysis that incorporates rNPV of two pipeline products, including: (1) Hemophilia B at a 70% POS driven by company’s clinical update as of September 23, 2018, vs. prior 65%; and (2) 5% POS. We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $981M, upped from $820M previously, during 2028.”

According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -3.5% and a 38.5% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $52, representing a 96.2% upside. In a report issued on October 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $58 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts